On behalf of Lilly, Seamless will design and programme recombinases that can correct alterations in multiple genes involved ...

That is the conclusion of the annual assessment of the sector's ability to attract financing by the BioIndustry Association ...

The list has been announced by the Centers for Medicare & Medicaid Services (CMS) shortly after the reductions agreed for the ...

A drug being developed by Boehringer Ingelheim for COVID-19 and reinvented as a potential therapy for kidney disease – and has now hit the mark in a phase 2 trial. TRPC6 inhibitor apecotrep (BI 764198 ...

Americans are particularly concerned with avoiding animal products. Indeed, a recent study published in the Postgraduate ...

Huahui Health has won the first approval in China for a drug to treat chronic infections with hepatitis D virus (HDV), ...

Boehringer Ingelheim has added another drug to its immunology pipeline, licensing an inflammatory bowel disease (IBD) ...

The UK has lost its measles elimination status, according to the World Health Organization (WHO), after recording 2,911 ...

At the JP Morgan Healthcare conference this year, a lot of the discourse around AI drug discovery focused on making the leap ...

The phase 2 trial of CT-388, a once-weekly subcutaneous injection acquired as part of its $2.7 billion takeover of Carmot ...

That is according to the Wall Street Journal, which has said MSD failed to reach an agreement with Revolution on a fair price ...